期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

拓扑替康结合替卡格雷治疗晚期卵巢癌伴血小板增多症疗效观察 被引量：4

下载PDF
导出
摘要 目的初步探讨抗血小板治疗对晚期卵巢癌的影响。方法以52例晚期卵巢癌患者为研究对象,分为治疗组及对照组,治疗组采用拓扑替康联合替卡格雷治疗,对照组仅采用拓扑替康常规治疗,分别检测2组治疗前后血小板水平,评价近期客观疗效。结果治疗组近期客观疗效优于对照组(P<0.05);2组患者血小板水平在治疗后比较有显著性差异(P<0.05)。结论替卡格雷抗血小板治疗晚期卵巢癌伴血小板增多症的患者具有应用前景,值得进一步研究。
作者 艾国华 丁岩
机构地区 广东省韶关市第一人民医院 复旦大学附属妇产科医院
出处 《现代中西医结合杂志》 CAS 2013年第11期1212-1213,共2页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 晚期卵巢癌 血小板 替卡格雷
分类号 R737.31 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1周易,王兰君,范丽昕.拓扑替康单药治疗顺铂耐药复发卵巢癌30例临床观察[J].中国民康医学,2011,23(22):2785-2785. 被引量：1
  • 2李春颖,吴鸣,原劲阳.血小板及纤维蛋白原对卵巢癌患者病情进展的影响[J].中国医学科学院学报,2009,31(1):81-83. 被引量：7
  • 3Friebe Z, Watrowski R, Bembnista M , et al. Correlation between p-latelet count and CA - 125 in ovarian cancer [ J ]. Ginekol Pol,2005,76(3) :187 - 194.
  • 4Kang H ,Kim TJ, Lee YY,et al . Topotecan combined with carbopl-atin in recurrent epithelial ovarian cancer:results of a single-institu-tional phase H study [ J ]. Gynecol Oncol,2009,114 ( 2 ) : 210 -214.
  • 5Muntz HG,Malpass TW,McGonigle KF, et al. Phase II study of intraperiton-eal to potecan as consol idation chemoth erapy in ovarianand primary periton-eal carcinoma[ J]. Cancer,2008,113(3) :490 -496.
  • 6Ma Y, Qian Y,Lv W. The correlation between plasma fibrinogen 1-evels and the clinical features of patients with ovarian carcinoma[J]. J Int Med Res,2007,35(5) :678 -684.
  • 7霍韶伟,郭晔堃,钟静芬,时惠麟.新型抗血小板药替卡格雷[J].上海医药,2012,33(3):21-23. 被引量：7

二级参考文献11

  • 1Cannistra S. Is there a best choice of the second - line agent in the treatment of recurrent potentially platinum - sensitive ovarian canc- er[ J ]. J C lin 0ncol,2002,20 (5) : 1158 - 1160.
  • 2Rowinsy EK, Grochow LB, Hendricks CB, et al. Phase I and phar- macological study of topotecan : a new novel topoisomerase I inhib- itor [ J]. J Clin Onco1,1992,10(4) :647-656.
  • 3Mcguire WP, Blessing JA, Bookman MA, et al. Topotecan has sub- stantial antitumor activity as first - line salvage therapy in platinum -sensitive epithelial ovarian carcinoma : a gynecologic oncologygroup study[ J]. J Clin Onco1,2000,18 ( 5 ) : 1062 - 1067.
  • 4Gore M ,Ten Bokkel, Huinink W, et al. Clinical evidence for topote- can - paclitaxel non - cross - resistance in ovarian cancer [ J ]. J Clin Oncol,2001,19 (7) :1893 - 1900.
  • 5Bookman MA, Malmstrom H, Bolis G, et al. Topotecan for the treat- ment of advanced epithelial ovarian cancer: an open label phase II study in patients treated after prior chemotherapy that contained cisp latin or carbop latin and paclitaxel [ J]. J Clin Oncol, 1998, 16:3345 - 3352.
  • 6Ghatak SB, Panchal SJ. Ticagrelor : a novel player in the field of anti-platelet therapy [J ]. J Pharm Res, 2010, 3(6) : 1271-1273.
  • 7Serebruany VL. Adenosine release : a potential explanation for the benefits of ticagrelor in the PLATelet Inhibition and Clinical Outcomes trial [ J ]. Am Heart J, 2011, 161(1) : 1-4.
  • 8Peters G, Robbie G. Single-dose pharmacokinetics and pharmacodynamics of AZD 6140-an oral reversible ADP receptor antagonist [ J ]. Haematologica, 2004, 89(Supp1 7) : 14-15.
  • 9Husted S, Emanuelsson H, Heptinstall S, et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD 6140 with aspirin in patients with atherosclerosis : a double-blind comparison to clopidogrel with aspirin [ J ]. Eur Heart J, 2006, 27(9) : 1038-1047.
  • 10余佩毅,郭文.抗血小板新药替卡格雷临床应用争议[J].世界临床药物,2010,31(5). 被引量：5

共引文献12

同被引文献41

  • 1Yang J, Chen L, Chitkara N, et al. A Markov model tocompare the long-term effect of aspirin, clopidogrel andclopidogrel plus aspirin on prevention of recurrentischemic stroke due to intracranial artery stenosis [J].Neurol India, 2014, 62(1): 48-52.
  • 2Zhang C J, Qiu H M, Qiu J P. Relationship ofpolymorphisms in the cholesteryl ester transport protein geneR451Q with coronary heart diseaseand diabetes in Uyghurand Han Chinese [J]. Genet Mol Res, 2014,13(1): 954-962.
  • 3Mahaffey K W, Held C, Wojdyla D M, et al. Ticagreloreffects on myocardial infarction and the impact of eventadjudication in the platelet inhibition and patientoutcomes (PLATO) trial [J]. J Am Coll Cardiol,2014,doi: 10.1016/j.jacc.2014.01.038.
  • 4Ross R.Atherosclerosis:an inflammatory disease[J].N Engl J Med,1999,340(2):115-126.
  • 5Rao AK,Pratt C,Berke A,et al.Thrombolysis in Myocardial Infarction(TIMI)Trial--phaseⅠ:hemorrhagic manifestations and changes in plasmafibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator andstreptokinase[J].J Am Coll Cardiol,1988,11(1):1-11.
  • 6Wallentin L,Richard BC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
  • 7Teng R,Mitchell PD,Butler K.Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteers[J].J Clin Pharm Ther,2012,37(4):464-468.
  • 8Butler K,Teng R.Pharmacokinetics,pharmacodynamics,safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers[J].Br J Clin Pharmacol,2010,70(1):65-77.
  • 9Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med,2009,361(11):1045-1057.
  • 10Cannon CP,Harrington RA,James S,et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes(PLATO):a randomised doubleblind study[J].Lancet,2010,375(9711):283-293.

引证文献4

二级引证文献56

现代中西医结合杂志
2013年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部